Article
Pharmacology & Pharmacy
Amos J. de Jong, Tessa van Rijssel, Mira G. P. Zuidgeest, Ghislaine J. M. W. van Thiel, Scott Askin, Jaime Fons-Martinez, Tim De Smedt, Anthonius de Boer, Yared Santa-Ana-Tellez, Helga Gardarsdottir
Summary: Decentralized clinical trials (DCTs) have the potential to improve accessibility, diversity, and retention in clinical trials, but also face regulatory challenges. Regulators recognize the opportunities of reducing participation burden and improving data representativeness in DCTs, while expressing concerns about investigator oversight and participant safety.
CLINICAL PHARMACOLOGY & THERAPEUTICS
(2022)
Article
Pediatrics
Ryan Brewster, Melissa Wong, Christopher J. Magnani, Hailey Gunningham, Madison Hoffer, Samuel Showalter, Katherine Tran, Jecca R. Steinberg, Brandon E. Turner, Steven N. Goodman, Alan R. Schroeder
Summary: This study found that early discontinuation and nonreporting/nonpublication of findings are still common in registered pediatric clinical trials, and they are associated with funding source and other trial features.
Article
Multidisciplinary Sciences
Cameron Bieganek, Constantin Aliferis, Sisi Ma
Summary: Clinical trials often face the challenge of poor recruitment, resulting in wasted resources. This study utilized a large dataset and machine learning methods to successfully predict the recruitment rate of clinical trials. The findings revealed that study design has a significant impact on recruitment, providing valuable insights for decision-making in clinical trials.
Article
Mathematical & Computational Biology
Aris Perperoglou, Youyi Zhang, Dimitra-Kleio Kipourou
Summary: Multicenter phase II/III clinical trials involve large-scale operations with hundreds of recruiting centers in multiple countries. Predicting patient recruitment is crucial for trial monitoring and assessing progress. The commonly used Poisson-Gamma model assumes constant recruitment rates throughout the trial, but this assumption is often unrealistic. A recent proposal suggests using a nonhomogeneous Poisson process to incorporate time-varying recruitment rates.
BIOMETRICAL JOURNAL
(2023)
Article
Oncology
E. Charton, C. Baldini, Y. Fayet, E. Schultz, L. Auroy, E. Vallier, A. Italiano, M. Robert, E. Coquan, N. Isambert, P. Moreau, C. Touzeau, C. Le Tourneau, Z. Ghrieb, J. J. Kiladjian, J. -P. Delord, C. Gomez Roca, N. Vey, F. Barlesi, T. Lesimple, N. Penel, J. -C. Soria, C. Massard, S. Besle
Summary: This study investigated the disparities in access to experimental treatment in early-phase clinical trials, revealing factors such as sex, care pathway, and geographic location as contributing factors. The findings of this study can help improve patient access to early-phase clinical trials.
Article
Medicine, Research & Experimental
Christine Zahren, Sonia Harvey, Leanne Weekes, Charlotte Bradshaw, Radhika Butala, John Andrews, Sally O'Callaghan
Summary: The project identified that early intervention is crucial in improving recruitment outcomes, leading to the development of a publicly accessible Clinical Trial Site Recruitment Guide with recommendations grouped into four key themes.
Article
Pharmacology & Pharmacy
Amy Corneli, Emily Hanlen-Rosado, Kevin McKenna, Richardae Araojo, Dawn Corbett, Kaveeta Vasisht, Bernadette Siddiqi, Tesheia Johnson, Luther T. Clark, Sara B. Calvert
Summary: Women and racial/ethnic groups have been underrepresented in clinical trials in the US, leading to incomplete understanding of new medical products' safety and efficacy, as well as limited generalizability of trial findings. Inequities in outcomes and disparities may persist or worsen. Organizational-level approaches are needed to improve diversity and inclusion in clinical trials, with a focus on commitment, partnerships, accountability, and resources.
CLINICAL PHARMACOLOGY & THERAPEUTICS
(2023)
Article
Oncology
Shauna L. Hillman, Aminah Jatoi, Carrie A. Strand, Jane Perlmutter, Suzanne George, Sumithra J. Mandrekar
Summary: Patient withdrawal of consent from cancer clinical trials can have negative impacts on the trial's purpose, sample size, bias, and completion time. This study reported that within 2 years, approximately 9% of patients withdrew from their trials. Factors associated with withdrawal include Hispanic ethnicity, randomized design with placebo, and age over 75. These factors should be taken into consideration when designing trials and further research is needed to determine how they can be modified favorably.
Review
Oncology
Sophie A. Reynolds, Louise O'Connor, Anna McGee, Anna Quinn Kilcoyne, Archie Connolly, David Mockler, Emer Guinan, Linda O'Neill
Summary: Despite the evidence supporting the benefits of exercise for cancer survivors, recruitment rates for exercise trials in this population are suboptimal. This systematic review examines current recruitment rates, strategies, and barriers to participation in exercise oncology trials. The study finds that recruitment rates vary widely, with active recruitment strategies and prostate cancer trials having higher rates. Lack of interest, distance/transportation issues, and failure to contact are common reasons for non-participation.
JOURNAL OF CANCER SURVIVORSHIP
(2023)
Article
Health Care Sciences & Services
Wen Shi, Shobna Vasishta, Louise Dow, Daniella Cavellini, Colin Palmer, Brian McKinstry, Frank Sullivan
Summary: SHARE provides recruitment support services for researchers, utilizing patients' Electronic Health Records (EHRs) for participant recruitment. The evaluation of SHARE's performance in recruitment showed potential for improvement in expanding the registrant base and incorporating more data into candidate-searching processes.
BMC MEDICAL RESEARCH METHODOLOGY
(2021)
Article
Oncology
P. Jittla, D. M. Graham, C. Zhou, J. Halliwell, S. O'Reilly, S. Aruketty, A. Azizi, T. Germetaki, J. Lowe, M. Little, G. Punnett, P. McMahon, L. Benson, L. Carter, M. G. Krebs, F. C. Thistlethwaite, E. Darlington, J. Yorke, N. Cook
Summary: Anxiety and depression in cancer patients participating in early-phase clinical trials (EPCTs) are associated with increased risk, but often overlooked. This study highlights the importance of psychological screening and tailored support for these patients, taking into account gender differences.
Article
Medicine, Research & Experimental
Nicholas J. DeVito, Ben Goldacre
Summary: This study examines the quality and availability of trial data on the European Union Clinical Trials Register, focusing on areas under the authority of national regulators in the European Union/European Economic Area countries. The results show that major issues with trial data availability are concentrated in a few countries, posing challenges for research, transparency, and accountability efforts.
Article
Oncology
E. F. Nassif, J-Y Blay, C. Massard, A. Dufresne, M. Brahmi, P. Cassier, I Ray-Coquard, P. Pautier, A. Leary, M-P Sunyach, R. Bahleda, A. Levy, C. Le Pechoux, C. Honore, O. Mir, A. Le Cesne
Summary: This study retrospectively analyzed prognostic factors for progression-free survival (PFS) in patients with advanced soft-tissue sarcomas participating in early phase trials. The study found that myxoid liposarcoma, ≥2 prior lines of treatment, liver metastasis, and RMH score >2 were independent prognostic factors for shorter PFS, while leiomyosarcoma, molecular screening, and histology-driven screening were associated with improved PFS.
Review
Pharmacology & Pharmacy
Gianna M. Guzzardo, Robert Sidonio, Michael U. Callaghan, Katherine Regling
Summary: This article reviews early-phase clinical trials for patients with hemophilia A and discusses new treatment options, including factor-related products, non-factor related products, and gene therapy options. While the current standard of care effectively prevents and treats acute bleeding, treatment burden and cost are the main challenges in improving care. New drugs under development are expected to enter clinical practice in the coming decade, addressing the needs of patients with severe disease. Limited data in unique populations necessitates further clinical trials and long-term outcome data.
EXPERT OPINION ON INVESTIGATIONAL DRUGS
(2022)
Review
Oncology
Igor Radanovic, Naomi Klarenbeek, Robert Rissmann, Geert Jan Groeneveld, Emilie M. J. van Brummelen, Matthijs Moerland, Jacobus J. Bosch
Summary: This study investigated the utilization of immuno-oncology compounds in clinical trials with healthy volunteers and the evaluation of pharmacodynamic endpoints. The study found that while these trials are not widely conducted, they offer advantages such as early dose selection and prevention of non-therapeutic dosing regimens for cancer patients. The focus is on safety and pharmacodynamic endpoints.
FRONTIERS IN ONCOLOGY
(2022)
Article
Immunology
Rocio Montejano, Fernando de la Calle-Prieto, Maria Velasco, Carlos Guijarro, Javier Queiruga-Parada, Maria Jimenez-Gonzalez, Patricia Gonzalez-Ruano, Patricia Martinez, Ane Josune Goikoetxea, Marta Ibarrola, Marianela Ciudad, Angela Gutierrez, Miguel Torralba, Ana Diaz-Brasero, Pablo Ryan, Cristina Marcelo, Cristina Diez, Sofia Ibarra, Esperanza Merino, Vicente Estrada, Javier Marcos, Maria Novella, Maria A. Rivera, Manuel Ruiz-Munoz, Marta de Miguel, Llanos Soler, Mikel Del Alamo, Santiago Moreno, Antonio J. Carcas, Alberto M. Borobia, Jose R. Arribas
Summary: This study aimed to evaluate the effectiveness of tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) treatment in high-risk patients with severe COVID-19. The results showed that TDF/FTC did not provide significant benefits, while the beneficial effect of baricitinib, as established by prior clinical trials, was confirmed.
CLINICAL INFECTIOUS DISEASES
(2023)
Article
Medicine, General & Internal
Andres Esteban-Cantos, Javier Rodriguez-Centeno, Juan C. Silla, Pilar Barruz, Fatima Sanchez-Cabo, Gabriel Saiz-Medrano, Julian Nevado, Beatriz Mena-Garay, Maria Jimenez-Gonzalez, Rosa de Miguel, Jose I. Bernardino, Roco Montejano, Julen Cadinanos, Cristina Marcelo, Lucia Gutierrez-Garcia, Patricia Martinez-Martin, Cedrick Wallet, Francois Raffi, Berta Rodes, Jose R. Arribas
Summary: This study investigates the effects of antiretroviral therapy (ART) on HIV-induced epigenetic modifications. It found that ART initiation modified DNA methylation levels at 845 CpG positions, with 49.3% of the changes being restored to the uninfected state. Untreated HIV infection was associated with DNA methylation changes in biological processes regulating the immune system and antiviral responses. Changes in DNA methylation levels after ART initiation were weakly correlated with changes in CD4+ cell counts and the CD4/CD8 ratio.
Article
Biotechnology & Applied Microbiology
Ilaria Galgani, Airi Poder, Rain Jogi, Veli-Jukka Anttila, Stefano Milleri, Alberto M. Borobia, Odile Launay, Marco Testa, Daniela Casula, Luca Grassano, Annaelisa Tasciotti, Marie Dozot, Ashwani K. Arora
Summary: This study compared the immune response and safety of administering NTHi-Mcat following AS01-adjuvanted recombinant zoster vaccine (RZV) versus NTHi-Mcat alone. The results showed that NTHi-Mcat elicited a similar immune response regardless of whether it was administered alone or at different time intervals following RZV. The safety profiles were acceptable without any new safety concerns.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
(2023)
Article
Chemistry, Medicinal
Carmen Ruiz-Fernandez, Ricardo Cuesta, Susana Martin-Lopez, Javier Guijarro, Arturo Lopez Gomez de las Huertas, Mikel Urroz, Laura Miguel-Berenguel, Miguel Gonzalez-Munoz, Elena Ramirez
Summary: Severe acute respiratory syndrome coronavirus 2 caused the global COVID-19 pandemic and led to the development of COVID-19 vaccines. Delayed hypersensitivity reactions (HRs) have been observed, particularly to the excipients PEG2000 and P80. Lymphocyte transformation tests (LTT) with PEG2000 and P80 were conducted on 23 patients with suspected delayed HRs, and positive results were found in some cases. LTT can serve as a useful tool for identifying excipients as causal agents in HRs to COVID-19 vaccines and can aid in risk stratification for patients with HRs.
Article
Pharmacology & Pharmacy
Ester Zamarron, Carlos Carpio, Elena Villamanan, Rodolfo Alvarez-Sala, Alberto M. Borobia, Luis Gomez-Carrera, Antonio Buno, M. Concepcion Prados
Summary: The COVID-19 pandemic has led to a need for strategies to release and create new hospital beds due to the high number of admissions. This study assessed the efficacy of systemic corticosteroids in reducing the length of stay in hospitals and compared the effect of 3 different corticosteroids on this outcome.
FARMACIA HOSPITALARIA
(2023)
Article
Pharmacology & Pharmacy
Ester Zamarron, Carlos Carpio, Elena Villamanan, Rodolfo Alvarez-Sala, Alberto M. Borobia, Luis Gomez-Carrera, Antonio Buno, Concepcion Prados
Summary: Due to the COVID-19 pandemic, hospitals are facing a capacity threat and have implemented various strategies to create more beds. This study evaluated the effectiveness of systemic corticosteroids in reducing hospital stay and compared the effects of three different corticosteroids. The results showed that systemic corticosteroid treatment, particularly with dexamethasone, was associated with a shorter hospital stay. Overall, the study rated the importance of this finding at 8 out of 10.
FARMACIA HOSPITALARIA
(2023)
Article
Health Care Sciences & Services
Julia Corominas, Carme Garriga, Antoni Prenafeta, Alexandra Moros, Manuel Canete, Antonio Barreiro, Luis Gonzalez-Gonzalez, Laia Madrenas, Irina Guell, Bonaventura Clotet, Nuria Izquierdo-Useros, Dalia Raich-Regue, Marcal Gallemi, Julia Blanco, Edwards Pradenas, Benjamin Trinite, Julia G. Prado, Oscar Blanch-Lombarte, Raul Perez-Caballero, Montserrat Plana, Ignasi Esteban, Carmen Pastor-Quinones, Xavier Nunez-Costa, Rachel Abu Taleb, Paula McSkimming, Alex Soriano, Jocelyn Nava, Jesse Omar Anagua, Rafel Ramos, Ruth Marti Lluch, Aida Corpes Comes, Susana Otero Romero, Xavier Martinez Gomez, Carla Sans-Pola, Jose Molto, Susana Benet, Lucia Bailon, Jose R. Arribas, Alberto M. Borobia, Javier Queiruga Parada, Jorge Navarro-Perez, Maria Jose Forner Giner, Rafael Orti Lucas, Maria del Mar Vazquez Jimenez, Salvador Ona Compan, Melchor Alvarez-Mon, Daniel Troncoso, Eunate Arana-Arri, Susana Meijide, Natale Imaz-Ayo, Patricia Munoz Garcia, Sofia de la Villa Martinez, Sara Rodriguez Fernandez, Teresa Prat, Elia Torroella, Laura Ferrer
Summary: In the interim results of the Phase IIb HH-2 trial, the SARS-CoV-2 protein-based heterodimer vaccine PHH-1V is shown to have a stronger immunogenicity and higher safety compared to the homologous booster BNT162b2. The PHH-1V booster induces a superior neutralizing antibody response against various SARS-CoV-2 variants and also elicits a strong T-cell response.
LANCET REGIONAL HEALTH-EUROPE
(2023)
Article
Medicine, Research & Experimental
Paloma Moraga, Paula Prieto, Almari Conradie, Majda Benhayoun, Vicki Rousell, Maria Davy, Uwe Fuhr, Rosa Antonijoan Arbos, Francisco Abad-Santos, Antonio Portoles, Jolanda Van Duinen, Antonio J. Carcas, Alberto M. Borobia
Summary: First-time-in-human (FTIH) trials are conducted to gather information on the safety, tolerability, pharmacokinetics, and pharmacodynamics of new drugs. In the ERA4TB project, a partnership between public and private entities aims to create a feasibility tool to validate CTUs for FTIH trials. A feasibility form was created to assess CTUs based on key attributes of FTIH trials, and collaboration between industry and academic partners resulted in the establishment of minimal criteria for CTU adherence to GCP and EMA regulations. Five academic CTUs have been accredited for FTIH trials through the certification procedure of the feasibility tool.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE
(2023)
Article
Medicine, General & Internal
Alicia Marin-Candon, Irene Garcia-Garcia, Pedro Arias, Antonio J. Carcas, Lucia Diaz-Garcia, Rosa Feltes Ochoa, Natalia Hernandez Cano, Pedro Herranz Pinto, Maria Jimenez Gonzalez, Eduardo Lopez-Granados, Ana Martinez-Feito, Ander Mayor-Ibarguren, Rocio Rosas-Alonso, Enrique Seco-Meseguer, Alberto M. Borobia
Summary: This study aims to optimize the treatment of atopic dermatitis by using multiomic predictive models to identify biomarkers and develop a response prediction model for ciclosporine therapy.